DON PEARSON, MD
Medical Practice at Bridgeport Way, Lakewood, WA

6693094, Feb 17, 2004

Mar 7, 2002

10/093476

Don C. Pearson - Lakewood WA
Kenneth T. Richardson - Anchorage AK

Chrono RX LLC - Anchorage AK

A61K 31555

514188, 51425506, 514456, 514458, 514494, 514505, 514565, 514593, 514635

The invention describes formulations that include either metformin, sulfonylurea or a biguanide-sulfonylurea combination as one active ingredient in addition to specific, other active ingredients. The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of the included biguanide (metformin) and/or sulfonylurea in the prevention and treatment of insulin resistance and diabetes mellitus. The carefully chosen additional active ingredients of the invention are designed in a modular fashion to prevent and rectify adverse events associated with insulin resistance syndrome and diabetes mellitus, and those adverse incidences associated with the concurrent use of metformin and/or the sulfonylureas. When clinically administered, the invention will provide therapeutic levels of metformin and of a sulfonylurea, alone or in combination, and broaden their usefulness. The invention will retard the progression of insulin resistance to type 2 diabetes, and reduce the serious microvascular and macrovascular complications commonly associated with insulin resistance syndrome and diabetes mellitus.

6524619, Feb 25, 2003

Jan 19, 2001

09/765974

Don C. Pearson - Lakewood WA
Kenneth T. Richardson - Anchorage AK

Chronorx, Inc. - Anchorage AK

A61K 920

424472, 424464, 424468

The invention defines interdependent biofactors and biomolecules, and clinically useful formulations that are comprised of them. The active agents are demonstrated to be complementary in their physiologic functions especially as these relate to the quenching of free radicals and to the support of endothelial physiology, the reduction of hyperinsulinemia and improvements in vascular health. The active components of the invention are selected for inclusion in precise combinations specifically because they improve these various conditions and physiological functions, and by so doing reduce a variety of risks associated with hearing loss and tinnitus. The resulting enhancement of general systemic vascular health, improvement in local VIII nerve vascular health, modulation of conditions surrounding blood fluid dynamics, the consequences of hyperinsulinemia, and improvements in free radical defenses, all reduce the potential for cochlear hair cell death and VIII nerve atrophy, and the hearing loss and possible deafness that accompany them.

6689385, Feb 10, 2004

Nov 2, 2001

10/033730

Kenneth T. Richardson - Anchorage AK
Don C. Pearson - Lakewood WA

Chronorx LLC - Anchorage AK

A61K 920

424464, 451472, 451482, 451486, 451489

The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of biguanides (metformin) and/or sulfonylureas in the prevention and treatment of insulin resistance and diabetes mellitus, alone or in combination, as a nutrient for humans. The carefully chosen active ingredients of the invention are designed in a modular fashion to prevent and rectify adverse events associated with insulin resistance syndrome and diabetes mellitus, and with the clinical use of biguanides (metformin) and/or the sulfonylureas. These modules are: (1) Mitochondrial Metabolic Group, (2) Plasma and Mitochondrial Membrane Integrity Group, (3) Nocturnal Group and, (4) Insulin Alternative Group. When used in concert with a biguanide, a sulfonylurea or with a combination of both, the invention will broaden the clinical usefulness of these drugs. The invention will retard the progression of insulin resistance to type 2 diabetes, and reduce the serious microvascular and macrovascular complications commonly associated with insulin resistance syndrome and diabetes mellitus.

6455061, Sep 24, 2002

Apr 5, 2001

09/828323

Kenneth T. Richardson - Anchorage AK
Don C. Pearson - Lakewood WA

ChronoRX, LLC - Anchorage AK

A61F 1300

424422, 424427, 424428, 514547, 514574

The components of this invention are chosen because of their complementarity for the prevention or treatment of diseases caused by the herpes simplex virus. L-Lysine favorably increases the physiologic immunomodulation necessary for defense against this virus. Zinc improves and maintains a normal immune response. 2-Deoxy-2-D-glucose and heparin sodium alter the surface interaction between the herpes virus and the cell, preventing fusion and infectivity. N-Acetyl-L-cysteine increases glutathione levels thereby creating a thiol redox barrier to the virus at the cell membrane. Quercetin reduces intracellular replication of the herpes virus and viral infectivity. Ascorbate, in concert with copper and D--tocopherol, provides an antioxidant defense against the herpes virus, which tends to lose latency during period of oxidative, free radical excess. Selenium and quercetin also participate in reducing various oxidative stresses. Together the components of this invention provide the potential for improved resistance to, improved recovery from, and a decreased frequency of recurrence of herpes simplex virus infection.

6632445, Oct 14, 2003

Jul 30, 2002

10/209432

Kenneth T. Richardson - Anchorage AK
Don C. Pearson - Lakewood WA

ChronoRX, LLC - Anchorage AK

A61E 1300

424422, 424 7804, 4242041, 4242291, 4242311, 424427

The components of this invention are chosen because of their complementarity for the prevention or treatment of diseases caused by the herpes simplex virus. L-Lysine favorably increases the physiologic immunomodulation necessary for defense against this virus. Zinc improves and maintains a normal immune response. 2-Deoxy-2-D-glucose and heparin sodium alter the surface interaction between the herpes virus and the cell, preventing fusion and infectivity. N-Acetyl-L-cysteine increases glutathione levels thereby creating a thiol redox barrier to the virus at the cell membrane. Quercetin reduces intracellular replication of the herpes virus and viral infectivity. Ascorbate, in concert with copper and D--tocopherol, provides an antioxidant defense against the herpes virus, which tends to lose latency during period of oxidative, free radical excess. Selenium and quercetin also participate in reducing various oxidative stresses. Together the components of this invention provide the potential for improved resistance to, improved recovery from, and a decreased frequency of recurrence of herpes simplex virus infection.

6531608, Mar 11, 2003

Jun 11, 2002

10/167630

Don C. Pearson - Lakewood WA
Kenneth T. Richardson - Anchorage AK

Chronorx, LLC. - Anchorage AK

C07D27702

548182, 556 45, 556110, 556118, 562557

This invention relates to the synthesis of certain complexes of cysteine, N-acetylcysteine, N-(2-mercaptopropionyl)glycine, and L-2-oxothiazolidine-4-carboxylate and to the nutritional use of these and other related individual or complexed thiol-contributing glutathione predecessors. Clinical uses for these molecules and complexes in the beneficial modification of various physiological conditions and functions associated with aging, chronic glaucoma, diabetes mellitus, insulin resistance, macular degeneration, neurodegenerative diseases and vasoconstriction are described in particular.

2006019, Aug 31, 2006

Jan 6, 2006

11/326796

Kenneth Richardson - Anchorage AK, US
Don Pearson - Lakewood WA, US
John Edwards - Los Altos CA, US

ChronoRX LLC, an Alaska Limited Liability Company - Anchorage AL

A61K 31/519, A61K 31/385

514250000, 514440000

Dosage forms and methods of use are disclosed for: a) the simultaneous administration of tetrahydrobiopterin (BH4) or a derivative, homolog or precursor thereof and lipoic acid (LA), or dihydrolipoic acid (DHLA), or a derivative, homolog or salt thereof or, b) the administration of a conjugate consisting of tetrahydrobiopterin bis-lipoate (TBL). The invention is useful for the amelioration of diabetes mellitus types 1 and 2 (including impaired glucose tolerance, pre-diabetes, insulin resistance, metabolic syndrome X and as an adjunct to oral antidiabetic agents and/or insulin), diabetic and non-diabetic microvascular diseases (including nephropathy, neuropathy and retinopathy), diabetic and non-diabetic macrovascular diseases (including heart attack, stroke, peripheral vascular disease and ischemia-reperfusion injury), hypertension, vasoconstriction, obesity, dyslipedemia, and neurodegenerative disorders (including Parkinson's disease, mild cognitive impairment, senile dementia, Alzheimer's disease, hearing loss and chronic glaucomas). A novel method for the preparation of TBL is also disclosed.

2011010, May 5, 2011

Apr 19, 2010

12/762639

Kenneth T. Richardson - Anchorage AK, US
Don C. Pearson - Lakewood WA, US

ChronoRX LLC, an Alaska Limited Liability Company - Anchorage AK

A61K 31/122, C07C 279/14, C07D 475/04, C07C 49/753, C07D 339/04, C07C 215/40, A61K 31/385, A61K 31/519, A61K 31/205, A61K 31/40, A61K 31/496, A61P 15/10, A61P 3/00

424 941, 562560, 544258, 568377, 549 39, 562567, 514440, 514249, 514556, 514423, 51425216

Dosage forms and methods of use are disclosed for a) adjuncts administered individually or simultaneously with HMg-CoA reductase inhibitors (statins) and/or selective phosphodiesterase 5 inhibitors or, b) the administration of a conjugate consisting of the adjuncts and an HMG-CoA reductase inhibitor and/or a selective phosphodiesterase 5 inhibitor. The invention is useful in the amelioration of side effects associated with HMG-CoA reductase inhibitors and will improve their effectiveness in diseases for which these are useful. The invention will also improve the effectiveness in the of selective phosphodiesterase 5 inhibitors in patients using these medications alone or in conjunction with statins, for the treatment of erectile dysfunction.

2009006, Mar 12, 2009

Nov 10, 2008

12/268244

Kenneth T. Richardson - Anchorage AK, US
Don C. Pearson - Lakewood WA, US
John A. Edwards - Los Altos CA, US

ChronoRX LLC - Anchorage AK

A61K 9/24, A61K 31/4985, A61P 3/10, A61P 3/00, A61P 3/06

424472, 514249

Dosage forms and methods of use are disclosed for: a) the simultaneous administration of tetrahydrobiopterin (BH4) or a derivative, homolog or precursor thereof and lipoic acid (LA), or dihydrolipoic acid (DHLA), or a derivative, homolog or salt thereof or, b) the administration of a conjugate consisting of tetrahydrobiopterin bis-lipoate (TBL). The invention is useful for the amelioration of diabetes mellitus types 1 and 2 (including impaired glucose tolerance, pre-diabetes, insulin resistance, metabolic syndrome X and as an adjunct to oral antidiabetic agents and/or insulin), diabetic and non-diabetic microvascular diseases (including nephropathy, neuropathy and retinopathy), diabetic and non-diabetic macrovascular diseases (including heart attack, stroke, peripheral vascular disease and ischemia-reperfusion injury), hypertension, vasoconstriction, obesity, dyslipedemia, and neurodegenerative disorders (including Parkinson's disease, mild cognitive impairment, senile dementia, Alzheimer's disease, hearing loss and chronic glaucomas). A novel method for the preparation of TBL is also disclosed.

6207190, Mar 27, 2001

Aug 11, 1999

9/372362

Kenneth T. Richardson - Anchorage AK
Don C. Pearson - Lakewood WA

ChronoRX, LLC - Anchorage AK

A61K9/24;9/22

424472

Four interdependent functional groups of biofactors and biomolecules are identified and formulations are defined which are comprised of their members. The active agents are demonstrated to be complementary in their physiological functions especially as these relate to endothelial biochemistry and physiology, hyperinsulinemia and, ultimately, to vascular health. The active components of the invention are selected for inclusion in precise combinations that reduce a variety of risks of vasculopathy in addition to reducing intraocular pressure. Widespread systemic improvement associated with local, optic nerve betterment of vascular health, reduces the risk of optic nerve atrophy with its accompanying visual field loss and potential blindness. The reduction of this maximizes the potential clinical therapeutic success of current medical, IOP-lowering, anti-glaucoma mediations.